Clinical Trial Update: Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit [Phase 3]

View source ↗

Summary

A Phase 3 trial of proxalutamide for COVID-19 in ICU settings was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars

Drugs mentioned

• proxalutamide (proxalutamide)

Snippet

Sponsor: Applied Biology, Inc. | Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Status: WITHDRAWN